| Document Date: 2014-11-03 11:26:24
Open Document File Size: 106,12 KBShare Result on Facebook
City Osaka / London / Florham Park / / Company The Shionogi-ViiV Healthcare LLC / GlaxoSmithKline / Pfizer Inc. / HIV/AIDS / Shionogi & Co. Ltd. / ViiV Healthcare Ltd. / Financial review / Shionogi Inc. / / Country Japan / United Kingdom / / Event FDA Phase / Business Partnership / / IndustryTerm pharmaceuticals / treatment of HIV / HIV therapy / healthcare / pharmaceutical / / MedicalCondition cancer / HIV / chronic / nausea / allergy / AIDS / Infectious Diseases / infection / / Person Tsutae "Den" Nagata / Dominique Limet / John Pottage / Sally Ferguson / Rebecca Hunt / / / Position Chief Executive Officer / Analyst / forward / Officer / Chief / / Product abacavir / lamivudine / HIV-1 / Dolutegravir / SPRING-2 / / ProvinceOrState New Jersey / / URL www.shionogi.co.jp / www.shionogi.com / www.viivhealthcare.com / /
SocialTag |
Shionogi-ViiV Healthcare Announces Initial Data from Pivotal Phase III Study of Dolutegravir in HIV SPRING-2 study meets primary endpoint of non-inferiority of dolutegravir compared to raltegravir over 48 weeks in treatm